Emerging Antibody-Drug Conjugates in Breast Cancer: An Expert Analysis of Promising Therapies

Did you know that different types of drug resistance to antibody-drug conjugates (ADCs) can develop at different sites in the same patient? How may this impact ADC sequencing?

Credit available for this activity expires: 12/13/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999152?ecd=bdc_podcast_libsyn_mscpedu